Docket-Specific Pre-Screen
What we confirm before every Tepezza lead is delivered
- Tepezza (teprotumumab) infusion treatment confirmed — administered by IV infusion.
- Condition being treated documented — thyroid eye disease (Graves' ophthalmopathy).
- Hearing loss or persistent tinnitus developed during or after Tepezza treatment.
- Audiological testing referenced where available — audiogram results documenting hearing loss.
- Treatment timeline captured — number of infusions received and dates.
- Horizon Therapeutics (now Amgen) identified as the manufacturer.
- SOL analyzed under discovery rule per diagnosis state.
- Not currently represented — confirmed before the lead leaves our system.
SOL Note
Tepezza hearing loss SOL follows the discovery rule — it runs from the date the claimant knew or should have known the hearing loss was connected to Tepezza. FDA label updates and published research are reference points for awareness.
The Market
The Tepezza market
Tepezza (teprotumumab) is prescribed for thyroid eye disease — the eye bulging and swelling associated with Graves' disease. It is administered as a series of IV infusions. Research and subsequent FDA label updates have linked Tepezza to hearing loss and persistent tinnitus in a significant percentage of patients. The 2021 Endocrine Society report and subsequent clinical studies documented rates of hearing dysfunction substantially higher than those identified in the original clinical trials.
Horizon Therapeutics (acquired by Amgen in 2023) faces consolidated litigation over failure to adequately warn of the hearing loss risk. The claimant population is patients who received Tepezza infusions for thyroid eye disease and developed measurable hearing loss or persistent tinnitus that did not resolve after treatment.
Why Tepezza leads need specialist qualification: the condition treated (thyroid eye disease) is uncommon, which narrows the claimant population. And the hearing loss must be measurable and persistent — temporary ringing during treatment that resolves is not part of the docket. Our pre-screen confirms both the condition treated and the persistent auditory effect before delivery.
Docket Pipeline
How Tepezza leads are qualified
Targeted Acquisition
Only people who matched your exact criteria submitted a form.
Form Pre-Screen
SOL, liability, insurance, and intent — all confirmed before delivery.
Tepezza pre-screen confirms infusion treatment for thyroid eye disease and persistent hearing loss or tinnitus.
OTP Phone Verification
The number is real. We proved it before you see it.
Exclusive Delivery
Your CRM. One firm. In under 15 seconds.
Pricing is per qualified lead — never a retainer, never a setup fee, never a monthly commitment. Calculate your all-in cost per signed retainer before you book the call.
Delivery Standards
How every lead arrives and what stands behind it
Every lead passes through four verification steps before delivery. Targeted acquisition drives intake traffic only from people who match your stated criteria. The form pre-screen documents SOL, liability, injury severity, and representation status. OTP phone verification confirms the number is real, active, and in possession of the claimant — not Google Voice, not a disconnected line, not a wrong number. Exclusive delivery places the lead into your CRM inside 15 seconds, locked to your firm ID with a permanent delivery timestamp.
Exclusivity is contractual, not verbal. Your client agreement contains a binding exclusivity term — every lead is sold to exactly one firm and there is no operational path for us to re-deliver it. TrustedForm certificates and Jornaya lead IDs travel with every lead as an independent consent audit trail, timestamped outside our own delivery system. The 48-hour credit exchange is written into your agreement as a contract term, not a return policy: expired SOL at delivery, liability that clearly does not hold based on pre-screen facts, case type mismatch, or represented-at-delivery all qualify without additional documentation. Your intake team’s assessment is sufficient.
Coverage runs in 38 states. Pricing is per qualified lead — no retainer, no setup fee, no monthly commitment. Volume can be paused or reduced with 30 days notice without penalty. Auto-connect puts your intake team on the phone with the claimant within 60 seconds of delivery, which is the single largest lever on contact-to-signed-retainer conversion in every vendor benchmark we have run. Firms routinely report 18–23% close rates on identical leads simply by moving first-call contact from 5 minutes to 60 seconds.
Read the full pipeline breakdown for operational detail on each verification step, or run your numbers with the cost-per-retainer calculator before booking a call.
Frequently Asked Questions
- Tepezza leads are priced at $550 per qualified lead as an emerging docket. No retainer. No setup fee.
Related dockets
The Arrangement
No retainer. No setup fee. No monthly commitment.
Start receiving verified leads in 5–7 days. One firm per case. Every lead OTP-verified. Credit exchange written into your client agreement.